Even though incidence of Hepatitis B is extremely low, it is recommended to continue hepatitis B vaccination which is currently included in the national immunization program.
SLHPBA Guidelines for the management of hepatocellular carcinoma in Sri Lanka -consensus statement
Prevention of HCC in Sri Lanka a. Hepatitis B vaccination
Even though incidence of Hepatitis B is extremely low, it is recommended to continue hepatitis B vaccination which is currently included in the national immunization program.
Screening for HCC in Sri Lanka a. Screening for HCC in cirrhotics
i. Six-monthly ultrasound scanning is recommended in screening cirrhotic patients.
Ÿ It is recommended to use a specially prepared request form within institutions indicating a clear clinical history.
b. Screening of high risk NASH groups.
i.Diabetics who are older than 40 years with elevated AST/ALT may be subjected to ultrasound scan screening.
Ÿ Frequency of screening is to be decided by the clinician as firm data is not yet available.
c. Hepatitis screening in Sri Lankan patients.
Ÿ Considering the extremely low incidence, screening for hepatitis B and C is likely to yield negative results. Nonavailability or delay in these reports should not delay the management of HCC. Sri Lanka has a rising population of patients with chronic liver cell disease. Incidence of metabolic liver disease in the country is one of the highest in the world [1] . Over the last 5 years, the number of HCC cases reported has steadily increased. HCC has become a disease of discussion due to rise in the incidence, recent accessibility of all treatment options, and availability of trained clinicians in managing HCC [2] .
There are regional guidelines published based on data from Europe, North America and East Asia. Infective hepatitis is rare in Sri Lankan patients. Apart from having a unique etiology, many practical difficulties are faced when directly applying these guidelines in the context of the local setting. In this background, Sri Lanka Hepato Pancreatico Biliary Association (SLHPBA) organized a consensus meeting to modify the already established clinical guidelines in a manner applicable to Sri Lanka.
In formulating the guidelines, feasibility and the local pattern of disease were considered. Overseas experts representing North America, Europe and India participated in the discussions. As local representatives, members representing Society of Gastroenterology, Radiology, Oncology, Pathology and General Surgery, participated in the discussions. Already published European association of study of liver disease guidelines [3] , Asia Pacific clinical practice guidelines 2017 [4] and American association of study of liver disease guidelines 2016 [5] , were used as a baseline platform. Each point was taken up, discussed and debated prior to an agreement. 
